Most individuals with prediabetes—defined by the presence of impaired glucose levels—are overweight or obese and could benefit from lifestyle changes to lose weight and reduce their risk of developing type 2 diabetes mellitus (T2DM). As lifestyle interventions are hard to implement and not effective over the long term in most individuals, could additional intervention with pharmacotherapy be warranted for the prevention of T2DM?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Nathan, D. M. et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 30, 753–759 (2007).
Rhee, M. K. et al. Many Americans have prediabetes and should be considered for metformin therapy. Diabetes Care 33, 49–54 (2010).
Knowler, W. C. et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346, 393–403 (2002).
Buchanan, T. A. et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 51, 2796–2803 (2002).
DREAM Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: randomised controlled trial. Lancet 368, 1096–1105 (2006).
Chaisson, J. L. et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359, 2072–2077 (2002).
Torgerson, J. S., Hauptman, J., Boldrin, M. N. & Sjöström, L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27, 155–161 (2004).
Diabetes Prevention Program Research Group. Effects of withdrawal from metformin on the development of diabetes in the Diabetes Prevention Program. Diabetes Care 26, 977–980 (2003).
Tuomilehto, J. et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 344, 1343–1350 (2001).
Xiang, A. et al. Effect of pioglitazone on pancreatic beta cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 55, 517–522 (2006).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
T. A. Buchanan declares associations with the following companies: Eli Lilly (speakers bureau), Takeda Pharmaceuticals North America (consultant, speakers bureau, grant/research support) Tethys Bioscience (consultant, stockholer). A. H. Xiang declares associations with the following companies: Takeda Pharmaceuticals North America (grant/research support), Tethys Bioscience (consultant).
Rights and permissions
About this article
Cite this article
Buchanan, T., Xiang, A. Preventing type 2 diabetes mellitus: is metformin the answer?. Nat Rev Endocrinol 6, 253–254 (2010). https://doi.org/10.1038/nrendo.2010.25
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2010.25